NCT06819215 Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
| NCT ID | NCT06819215 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 188 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 188 participants in total. It began in 2024-10-30 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 at the time of screening; * Histological or cytological confirmation of advanced malignancy ; * Progressive cancer at the time of study entry; * Adequate organ and marrow function as defined by the protocol; * Homologous recombination repair gene mutation. Exclusion Criteria: * Major surgery within 4 weeks of the first dose of study treatment. * Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded. * Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06819215 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06819215 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06819215 currently recruiting?
Yes, NCT06819215 is actively recruiting participants. Contact the research team at songjia@vybio.com for enrollment information.
Where is the NCT06819215 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06819215 clinical trial?
NCT06819215 is sponsored by Zhejiang Yangli Pharmaceutical Technology Co., Ltd.. The trial plans to enroll 188 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.